| Item type |
文献 / Documents(1) |
| 公開日 |
2018-11-12 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1111/cas.12985 |
|
|
関連名称 |
10.1111/cas.12985 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model |
| タイトル別表記 |
|
|
その他のタイトル |
Anti-podoplanin antibody against MPM |
| 著者 |
阿部, 真治
カトウ カネコ, ミカ
ツチハシ, ユウキ
イズミ, トシヒロ
オガサワラ, サトシ
岡田, 直人
佐藤, 智恵美
飛梅, 亮
大塚, 憲司
宮本, 理人
土屋, 浩一郎
川添, 和義
カトウ, ユキナリ
西岡, 安彦
|
| 抄録 |
|
|
内容記述 |
Podoplanin (aggrus) is highly expressed in several types of cancers, including malignant pleural mesothelioma (MPM). Previously, we developed a rat anti-human podoplanin mAb, NZ-1, and a rat–human chimeric anti-human podoplanin antibody, NZ-8, derived from NZ-1, which induced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against podoplanin-positive MPM cell lines. In this study, we showed the antitumor effect of NZ-1, NZ- 8, and NZ-12, a novel rat–human chimeric anti-human podoplanin antibody derived from NZ-1, in an MPM orthotopic xenograft SCID mouse model. Treatment with NZ-1 and rat NK (CD161a+) cells inhibited the growth of tumors and the production of pleural effusion in NCI-H290/PDPN or NCI-H226 orthotopic xenograft mouse models. NZ-8 and human natural killer (NK) (CD56+) cells also inhibited tumor growth and pleural effusion in MPM orthotopic xenograft mice. Furthermore, NZ-12 induced potent ADCC mediated by human MNC, compared with either NZ-1 or NZ-8. Antitumor effects were observed following treatment with NZ-12 and human NK (CD56+) cells in MPM orthotopic xenograft mice. In addition, combined immunotherapy using the ADCC activity of NZ-12 mediated by human NK (CD56+) cells with pemetrexed, led to enhanced antitumor effects in MPM orthotopic xenograft mice. These results strongly suggest that combination therapy with podoplanin-targeting immunotherapy using both NZ-12 and pemetrexed might provide an efficacious therapeutic strategy for the treatment of MPM. |
| キーワード |
|
|
主題 |
antibody-dependent cellular cytotoxicity |
| キーワード |
|
|
主題 |
mesothelioma |
| キーワード |
|
|
主題 |
NZ-12 |
| キーワード |
|
|
主題 |
orthotopic xenograft model |
| キーワード |
|
|
主題 |
podoplanin |
| 書誌情報 |
en : Cancer Science
巻 107,
号 9,
p. 1198-1205,
発行日 2016-06-13
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13497006 |
| 出版者 |
|
|
出版者 |
Japanese Cancer Association |
| 権利情報 |
|
|
権利情報 |
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| EID |
|
|
識別子 |
327447 |
| 言語 |
|
|
言語 |
eng |
cas_107_9_1198.pdf (937 KB)
